Clinical Trial

Mechanisms for Activation of Beige Adipose Tissue in Humans

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-25 -> 2027-06 2026-07-08
minor Completion pushed: 2026-12-01 -> 2027-12 2026-07-08
Trial Details
NCT Number NCT04666636
Lead Sponsor Philip Kern
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions PreDiabetes
Enrollment 65 participants
Start Date 2020-12-07
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-07